biotech / news / / Livemint
Gujarat Themis Biosyn shares jumped over 15% on Friday, 24 April as the company prepares to acquire a range of anti-tuberculosis (TB) and anti-infective brands from Sanofi.
Gujarat Themis Biosyn will acquire 13 anti-TB and anti-infective brands from Sanofi for €158 million.
KEY POINTS
- The acquisition covers commercial rights but excludes manufacturing facilities and personnel, ensuring asset-light expansion.
- The acquired portfolio reported net sales of €62 million for fiscal year ending 2025.
- This transaction is nearly 50% of Gujarat Themis Biosyn's current market capitalization.
COMPANIES
Summarized by Newsio from Livemint. How we summarize →